慢性粒细胞白血病
髓系白血病
靶向治疗
医学
微小残留病
伊马替尼
酪氨酸激酶
癌症研究
癌症
白血病
免疫学
肿瘤科
内科学
受体
作者
Martin H. Luu,Richard D. Press
标识
DOI:10.1586/14737159.2013.835573
摘要
The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) represents the paradigm for modern targeted cancer therapy. Importantly, molecular monitoring using BCR-ABL real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) for assessing treatment efficacy and quantitating minimal residual disease is a major determinate of practical therapeutic decision-making in the long-term management of this now chronic disease. Herein, we present an overview of CML and the use of TKIs for targeted CML therapy, with an emphasis on the role, application and future aspects of PCR-based molecular monitoring.
科研通智能强力驱动
Strongly Powered by AbleSci AI